Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the study population

From: Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study

  Patients receiving VKA (n = 1008) Patients receiving NOAC (n = 552) P value
Median age (IQR) 78.00 (71.00–84.00) 80.00 (72.00–86.00) < 0.001
Male (%) 645 (64.0) 314 (56.9) 0.007
Oral anticoagulation < 0.001
 Apixaban (%)   302 (54.7)  
 Dabigatran (%)   80 (14.5)  
 Rivaroxaban (%)   170 (30.8)  
 VKA (%) 1008 (100.0)   
Income group (quartiles) < 0.001
 1st (lowest) 382 (37.9) 143 (25.9)  
 2nd 297 (29.5) 165 (29.9)  
 3rd 208 (20.6) 159 (28.8)  
 4th (highest) 121 (12.0) 85 (15.4)  
Comorbidity
 Hypertension 914 (90.7) 494 (89.5) 0.454
 Previous stroke (%) 175 (17.4) 102 (18.5) 0.629
 Previous bleeding (%) 256 (25.4) 122 (22.1) 0.164
 Heart failure (%) 395 (39.2) 195 (35.3) 0.147
 Ischemic heart disease (%) 440 (43.7) 231 (42.9) 0.492
 Peripheral artery disease (%) 101 (10.0) 63 (11.4) 0.391
 Diabetes (%) 260 (25.8) 141 (25.5) 0.962
 Liver disease (%) 28 (2.8) 19 (3.4) 0.563
 Alcohol abuse (%) 38 (3.8) 31 (5.6) 0.117
Comedication
 ADPi (%) 164 (16.3) 107 (19.4) 0.138
 Aspirin (%) 537 (53.3) 277 (50.2) 0.264
 Statin (%) 503 (49.9) 275 (49.8) 1.000
 Beta-blocker (%) 582 (57.7) 303 (54.9) 0.302
 RASi (%) 524 (52.0) 294 (53.3) 0.667
 NSAID (%) 116 (11.5) 69 (12.5) 0.619
  1. Abbreviations: IQR Interquartile Range, ADPi Adenosine diphosphate inhibitor, VKA Vitamin K antagonist, RASi Renin angiotensin system inhibitor, NOAC Nonvitamin K oral anticoagulants, NSAID Non-steroid anti-inflammatory drugs